A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Trial Profile

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Tisagenlecleucel (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ENSIGN
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Sep 2018 Results from ELIANA and ENSIGN trials, were published in the Clinical Cancer Research.
    • 17 Jun 2018 Results assessing Immunogenicity from ELIANA, ENSIGN and JULIET trials presented at the 23rd Congress of the European Haematology Association
    • 17 Jun 2018 Results from ELIANA and ENSIGN trials presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top